| | | | | S-ii | | | |
| | | | | S-iv | | | |
| | | | | S-1 | | | |
| | | | | S-5 | | | |
| | | | | S-7 | | | |
| | | | | S‑8 | | | |
| | | | | S-10 | | | |
| | | | | S-11 | | | |
| | | | | S-16 | | | |
| | | | | S-23 | | | |
| | | | | S-23 | | | |
| | | | | S-23 | | | |
| | | | | S-23 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 17 | | | |
| | | | | 24 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 29 | | | |
| | | | | 30 | | | |
| | | | | 32 | | | |
| | | | | 34 | | | |
| | | | | 34 | | |
| | |
As of March 31, 2021
|
| |||||||||
| | |
Actual
|
| |
As Adjusted
|
| ||||||
| | |
(unaudited)
(in thousands) |
| |||||||||
Cash, cash equivalents and available for sale securities(1)
|
| | | $ | 180,201 | | | | | $ | | | |
Preferred stock, par value $0.001 per share; 5,000,000 shares authorized, no shares
issued or outstanding, actual and as adjusted |
| | | | — | | | | | | — | | |
Common stock, $0.001 par value: 200,000,000 shares authorized, actual and as
adjusted; 90,169,616 shares issued and outstanding, actual; shares issued and outstanding, as adjusted |
| | | | 90 | | | | | | | | |
Additional paid-in capital
|
| | | | 758,964 | | | | | | | | |
Accumulated deficit
|
| | | | (591,868) | | | | | | | | |
Accumulated other comprehensive income
|
| | | | 2 | | | | | | | | |
Total stockholders’ equity
|
| | | | 167,188 | | | | | | | | |
Total capitalization
|
| | | $ | 347,389 | | | | | $ | | | |
|
Public offering price per share
|
| | | | | | | | | $ | | | |
|
Net tangible book value per share as of March 31, 2021
|
| | | $ | 1.85 | | | | | | | | |
|
Increase in net tangible book value per share attributable to new investors in this offering
|
| | | $ | | | | | | | | | |
|
As adjusted net tangible book value per share after this offering
|
| | | | | | | | | $ | | | |
|
Dilution per share to new investors in this offering
|
| | | | | | | | | $ | | |
Underwriter
|
| |
Number of
Shares |
| | | |
Cowen and Company, LLC
|
| |
|
| | ||
Credit Suisse Securities (USA) LLC
|
| | | | | ||
Stifel, Nicolaus & Company, Incorporated
|
| | | | | ||
Wedbush Securities Inc.
|
| | | | | ||
Total
|
| | | | |
| | |
Total
|
| ||||||
| | |
Per Share
|
| |
Without
Exercise of Option to Purchase Additional Shares |
| |
With Full
Exercise of Option to Purchase Additional Shares |
|
Public offering price
|
| | | | | | | | | |
Underwriting discount
|
| | | | | | | | | |
Proceeds, before expenses, to IVERIC bio, Inc.
|
| | | | | | | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 17 | | | |
| | | | | 24 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 29 | | | |
| | | | | 30 | | | |
| | | | | 32 | | | |
| | | | | 34 | | | |
| | | | | 34 | | |
|
Cowen
|
| |
Credit Suisse
|
| |
Stifel
|
|